PC
EUCRW

Periscope Capital’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Periscope Capital’s Portfolio EUCRW Stock Details EUCRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,300
Closed -$851 – 842
2022
Q4 		$851 Hold
15,300
– – ﹤0.01% 910
2022
Q3 		$1K Sell
15,300
-10,900
-42% -$690 ﹤0.01% 1140
2022
Q2 		$2K Buy
+26,200
New +$4.21K ﹤0.01% 1156

Other funds holding EUCRW

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Periscope Capital's EUCRW Position: Q1 2023 in Review

Periscope Capital sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q1 2023, closing a stake of 15,300 shares — an estimated $851 sold.

Periscope Capital first reported a position in EUCRW in Q2 2022 and held it in 3 quarters. The position peaked at $2K in Q2 2022. 22 funds tracked by Wall St. Rank hold EUCRW as of Q1 2023.

  • Periscope Capital reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
  • Periscope Capital sold 15,300 Eucrates Biomedical Acquisition Corp. Warrant shares in Q1 2023, an estimated $851.
  • Periscope Capital first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q2 2022 and held it in 3 quarters.
  • Periscope Capital's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $2K in Q2 2022.
  • 22 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q1 2023.

Based on Periscope Capital's 13F filing for Q1 2023, filed 12 May 2023.